Diabetes Drug Could Help Smokers Kick the Habit
University of Texas Health Science Center at HoustonA diabetes drug is being enlisted in the war against smoking by UTHealth researchers.
A diabetes drug is being enlisted in the war against smoking by UTHealth researchers.
Taking a pharmaceutical formulation of cannabidiol, a cannabis-based medicine, cut seizures nearly in half for children with a rare and severe type of epilepsy called Dravet syndrome, according to a phase 3 study released today that will be presented at the American Academy of Neurology’s 71st Annual Meeting in Philadelphia, May 4 to 10, 2019. Dravet syndrome, which starts in infancy, can lead to intellectual disability and frequent, prolonged seizures. Cannabidiol is derived from marijuana that does not include the psychoactive part of the plant that creates a “high.”
Ablacon, Inc. (www.ablacon.com), a Wheat Ridge, CO-based company developing an advanced mapping system to guide the treatment of atrial fibrillation (AFib)
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have been awarded a $4.6 million grant from the California Institute for Regenerative Medicine – also known as CIRM – to support a phase I clinical trial of a novel treatment for advanced sarcomas and other cancers with a specific tumor marker called NY-ESO-1.
A USC Norris study aims to increase clinical trial enrollment among low-income patients and racial and ethnic minorities by offering financial assistance for out-of-pocket costs associated with the trial. Because patients from low-income and racial minorities enroll in clinical trials at much lower rates, researchers are not capturing accurate data about personalized cancer care within these groups.
Penn Nursing’s Rosemary Polomano, PhD, RN, FAAN, Associate Dean for Practice Professor of Pain Practice, and M. Kit Delgado, MD, MS, Assistant Professor of Emergency Medicine and Epidemiology at Penn’s Perleman School of Medicine, have been appointed members of the National Academies of Sciences, Engineering, and Medicine’s (the Academies) Committee on Evidence-based Clinical Practice Guidelines to Prescribing Opioids for Acute Pain.
An investigational drug that may block harmful antibodies from passing through the placenta of an expectant mother to the fetus is the focus of a new clinical trial led by Kenneth Moise, MD, a maternal-fetal medicine specialist at UTHealth.
Researchers at University of California San Diego School of Medicine found using blood thinners in patients with worsening heart failure, coronary artery disease and irregular heart rhythms was associated with a reduced risk of thromboembolic events, such as stroke and heart attack.
Fire ecologists and wildlife specialists at La Trobe University have made key discoveries in how wildlife restores itself after bushfires
University of California San Diego School of Medicine researchers found that treating patients with personalized precision medicine that combined therapies to target multiple alterations improved outcomes in patients with therapy resistant cancers.
Fight CRC’s Clinical Trial Finder App aims to make the web-based resource more accessible to Late-State, MSS colorectal cancer patients
• The Time to Reduce Mortality in ESRD (TiME) trial was a large pragmatic trial demonstration project designed to determine the benefits of hemodialysis sessions that are longer than many patients currently receive. • The trial was conducted through a partnership between academic investigators and 2 large dialysis provider organizations using a highly centralized implementation approach. • Although the trial accomplished most of its demonstration project objectives, uptake of the intervention was insufficient to determine whether longer sessions improve outcomes.
The University of Chicago will lead the NRG Oncology Statistics and Data Management Center, which is receiving six more years of funding from the National Cancer Institute.
New research suggests that the microbial communities associated with chronic wounds common in diabetic patients affect whether those wounds heal or lead to amputations.
Small children may one day avoid invasive, painful and often traumatic oesophageal tube-testing for gut damage and coeliac disease with a new method of simply blowing into a glass tube to provide effective diagnoses. Research published in international journal Scientific Reports describes an exciting new breath test that could have global implications on how to detect gastrointestinal damage.
“Magic mouthwash,” an oral rinse containing diphenhydramine, lidocaine and antacids, significantly reduced pain from oral mucositis, mouth sores, in patients receiving radiation therapy for cancers of the head and neck when compared to plaecbo. These were the findings of a multi-institution, randomized, double-blind, placebo-controlled, phase III clinical trial, led by Robert Miller, M.D., an emeritus Mayo Clinic radiation oncologist. Dr. Miller and his colleagues published their findings on Tuesday, April 16, in JAMA.
Patient-reported outcomes (PROs) are an important target for efforts to improve healthcare – focusing on the most important problems and outcomes identified by patients themselves. A special supplement to Medical Care presents a toolkit of methods to help personalize care for patients with cancer using a 'PRO cision Medicine' approach. The journal is published in the Lippincott portfolio by Wolters Kluwer.
UC San Francisco is collaborating with the nonprofit Lazarex Cancer Foundation on a three-year study to identify ways to improve cancer clinical trial participation among medically underserved populations, including low-income individuals and racial and ethnic minorities.
Doctors promote prevention during Oral and Head and Neck Cancer Awareness Month
Hematology researchers have further refined how a treatment currently used urgently to control bleeding in hemophilia patients holds promise for prevention as well. A study in animals may lead to a new therapy for patients who now develop antibodies to the standard maintenance treatment.
Through partnerships with Sanofi Argentina, Sanofi Chile, Sanofi Colombia, Sanofi Pacific and Caribbean, Sanofi Peru and Sanofi Uruguay, the Endocrine Society hosted its first Latin American (LATAM) Leadership Academy. Sixty-two clinicians from over 15 countries across South America, Central America and the Caribbean took part in a one-day leadership training program and attended ENDO 2019, the annual meeting of the Endocrine Society, in New Orleans, La.
Georgetown University faculty offer expertise for journalists seeking interviews in a variety of subjects related to Ebola. Topics include WHO, Public Health Emergency of International Concern (PHEIC), International Health Regulations, infectious disease control and treatment, vaccine development, clinical trials, and global health security and law.
Dr. Leena Pattarkine and Dr. Shailaja Agrawal are partnering with students to design and fabricate a tool that will aid in the growth of cell cultures via a 3D platform. Launched this spring, the “Biopolymer Sponge Microfluidics for Continuous 3D Cell Culture and Drug Screening Project” aims to transform the field of drug screening and make it much more cost effective.
Southern Research and Japan’s Ina Research announced today they have formed a partnership that calls for Ina to help connect Southern Research with potential new customers for drug development services in the country with the world’s third largest pharmaceutical industry.
Below are summaries of recent Fred Hutch research, with links for additional background and media contacts.
ASCO, ASH, and NCCN receive letter clarifying CDC Guideline for Prescribing Opioids for Chronic Pain not meant to limit access to appropriate pain management for individuals with cancer, sickle cell disease
A glimpse into the future of global public health: a credit-card sized piece of paper is dunked into a liquid sample at a health clinic in a developing nation, quickly telling a doctor or nurse whether a malnourished child with diarrhea is infected with a virus, a bacteria, or a parasitic protozoan.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American College of Radiology (ACR) announce a new collaborative clinical data registry to support high-quality practice and patient care. The registry will allow collection and analysis of data on nuclear medicine procedures, supporting continuous improvement of patient care.
In January scientists at Vanderbilt University Medical Center (VUMC) and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus.
Researchers are investigating whether monitoring brain tissue oxygen levels in patients with severe traumatic brain injury (TBI) results in higher rates of survival and functionality. The trial at The University of Texas Health Science Center at Houston (UTHealth) is part of a nationwide study that is funded by the National Institutes of Health.
The U.S. Food and Drug Administration’s approval today of atezolizumab (Tecentriq®, Genentech) in combination with chemotherapy (carboplatin and etoposide) for the initial treatment of extensive-stage small cell lung cancer (SCLC) marks the end of numerous failed attempts to improve survival for those with the deadly disease.
The 33 million people with atrial fibrillation worldwide not only suffer from bothersome symptoms, but also face a fivefold increased risk of stroke and a twofold increased risk of death. Research teams led by Mayo Clinic published three connected studies on Friday, March 15, clarifying the benefits of catheter ablation versus rate- or rhythm-control medications to treat atrial fibrillation.
New preclinical data from University of California San Diego School of Medicine and Moores Cancer Center offers proof-of-principle for a combination immunotherapy that suppresses tumor growth in the liver. Current therapies for liver cancer are largely ineffective, resulting in poor outcomes.
Findings in Journal of the National Cancer Institute shows patients don’t have enough opportunities for participation